Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation

Clinical Immunology

Volumn 142, Issue 1, 2012, Pages 84-92

  Espejo, Carmen ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

4 aminopyridine; ; Dalfampridine; ; Fampridine SR; ; Multiple sclerosis; ; Potassium channel blocker; Symptomatic treatment;

Indexed keywords

4 AMINOPYRIDINE; CALCIUM CHANNEL; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM ION; GRANZYME B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERLEUKIN 12; NEUROTRANSMITTER; POTASSIUM CHANNEL BLOCKING AGENT; QUINIDINE; REACTIVE OXYGEN METABOLITE;

ALLERGIC NEUROPATHY; CALCIUM SIGNALING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG POTENTIATION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; MEMORY CELL; MULTIPLE SCLEROSIS; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NERVE CELL; NEUROMUSCULAR FUNCTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SLOW DRUG RELEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION;

4-AMINOPYRIDINE; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MULTIPLE SCLEROSIS; POTASSIUM CHANNEL BLOCKERS;

EID: 84856223165     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2011.06.004     Document Type: Review

References (113)

1. N.M.S.Society About MS: who gets MS? http://www.nationalmssociety.org/about-multiple-sclerosis/what-we-know-about-ms/who-gets-ms/index.aspx.
2. Lassmann H., Raine C.S., Antel J., Prineas J.W. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J. Neuroimmunol. 1998, 86:213-217.
3. Ingram D.A., Thompson A.J., Swash M. Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. J. Neurol. Neurosurg. Psychiatry 1988, 51:487-494.
4. Namerow N.S., Enns N. Visual evoked responses in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1972, 35:829-833.
5. Davis F.A., Jacobson S. Altered thermal sensitivity in injured and demyelinated nerve. A possible model of temperature effects in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1971, 34:551-561.
6. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 2000, 343:938-952.
7. Hayes K.C. The use of 4-aminopyridine (fampridine) in demyelinating disorders. CNS Drug Rev. 2004, 10:295-316.
8. Judge S.I., Bever C.T. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol. Ther. 2006, 111:224-259.
9. Schafer E.W., Brunton R.B., Cunningham D.J. A summary of the acute toxicity of 4-aminopyridine to birds and mammals. Toxicol. Appl. Pharmacol. 1973, 26:532-538.
10. Schafer E.W., Brunton R.B., Lockyer N.F. The effects of subacute and chronic exposure to 4-aminopyridine on reproduction in coturnix quail. Bull. Environ. Contam. Toxicol. 1975, 13:758-764.
11. Thompson S. Aminopyridine block of transient potassium current. J. Gen. Physiol. 1982, 80:1-18.
12. Targ E.F., Kocsis J.D. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res. 1985, 328:358-361.
13. Pongs O. Molecular biology of voltage-dependent potassium channels. Physiol. Rev. 1992, 72:S69-S88.
14. Miller R.D., Booij L.H., Agoston S., Crul J.F. 4-Aminopyridine potentiates neostigmine and pyridostigmine in man. Anesthesiology 1979, 50:416-420.
15. Agoston S., Salt P.J., Erdmann W., Hilkemeijer T., Bencini A., Langrehr D. Antagonism of ketamine-diazepam anaesthesia by 4-aminopyridine in human volunteers. Br. J. Anaesth. 1980, 52:367-370.
16. Agoston S., Maestrone E., Van Hezik E.J., Ket J.M., Houwertjes M.C., Uges D.R. Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J. Clin. Invest. 1984, 73:1291-1296.
17. Gay R., Algeo S., Lee R., Olajos M., Morkin E., Goldman S. Treatment of verapamil toxicity in intact dogs. J. Clin. Invest. 1986, 77:1805-1811.
18. Agoston S., Van Weerden T., Westra P., Broekert A. Effects of 4-aminopyridine in Eaton Lambert Syndrome. Br. J. Anaesth. 1978, 50:383-385.
19. Ball A.P., Hopkinson R.B., Farrell I.D., Hutchison J.G., Paul R., Watson R.D., Page A.J., Parker R.G., Edwards C.W., Snow M., Scott D.K., Leone-Ganado A., Hastings A., Ghosh A.C., Gilbert R.J. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q. J. Med. 1979, 48:473-491.
20. Kim Y.I., Goldner M.M., Sanders D.B. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. Muscle Nerve 1980, 3:112-119.
21. Lundh H., Nilsson O., Rosen I. 4-aminopyridine-a new drug tested in the treatment of Eaton-Lambert syndrome. J. Neurol. Neurosurg. Psychiatry 1977, 40:1109-1112.
22. Lundh H., Nilsson O., Rosen I. Effects of 4-aminopyridine in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 1979, 42:171-175.
23. Wesseling H., Agoston S., Van Dam G.B., Pasma J., Dewit D.J., Havinga H. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease. N. Engl. J. Med. 1984, 310:988-989.
24. Bostock H., Sears T.A., Sherratt R.M. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J. Physiol. 1981, 313:301-315.
25. Sherratt R.M., Bostock H., Sears T.A. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980, 283:570-572.
26. Shi R., Blight A.R. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 1997, 77:553-562.
27. Shi R., Kelly T.M., Blight A.R. Conduction block in acute and chronic spinal cord injury: different dose-response characteristics for reversal by 4-aminopyridine. Exp. Neurol. 1997, 148:495-501.
28. Bowe C.M., Kocsis J.D., Targ E.F., Waxman S.G. Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann. Neurol. 1987, 22:264-268.
29. Gold M.S., Shuster M.J., Levine J.D. Characterization of six voltage-gated K+ currents in adult rat sensory neurons. J. Neurophysiol. 1996, 75:2629-2646.
30. Lemeignan M., Millart H., Lamiable D., Molgo J., Lechat P. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res. 1984, 304:166-169.
31. Thesleff S. Aminopyridines and synaptic transmission. Neuroscience 1980, 5:1413-1419.
32. Goodman A.D., Brown T.R., Cohen J.A., Krupp L.B., Schapiro R., Schwid S.R., Cohen R., Marinucci L.N., Blight A.R. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008, 71:1134-1141.
33. Goodman A.D., Brown T.R., Edwards K.R., Krupp L.B., Schapiro R.T., Cohen R., Marinucci L.N., Blight A.R. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann. Neurol. 2010, 68:494-502.
34. Goodman A.D., Brown T.R., Krupp L.B., Schapiro R.T., Schwid S.R., Cohen R., Marinucci L.N., Blight A.R. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373:732-738.
35. Goodman A.D., Cohen J.A., Cross A., Vollmer T., Rizzo M., Cohen R., Marinucci L., Blight A.R. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult. Scler. 2007, 13:357-368.
36. Chwieduk C.M., Keating G.M. Dalfampridine extended release: in multiple sclerosis. CNS Drugs 2010, 24:883-891.
37. Kachuck N.J. Sustained release oral fampridine in the treatment of multiple sclerosis. Expert. Opin. Pharmacother. 2009, 10:2025-2035.
38. Hayes K.C., Katz M.A., Devane J.G., Hsieh J.T., Wolfe D.L., Potter P.J., Blight A.R. Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J. Clin. Pharmacol. 2003, 43:379-385.
39. Hayes K.C., Potter P.J., Hansebout R.R., Bugaresti J.M., Hsieh J.T., Nicosia S., Katz M.A., Blight A.R., Cohen R. Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clin. Neuropharmacol. 2003, 26:185-192.
40. Hayes K.C., Potter P.J., Hsieh J.T., Katz M.A., Blight A.R., Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch. Phys. Med. Rehabil. 2004, 85:29-34.
41. Uges D.R., Sohn Y.J., Greijdanus B., Scaf A.H., Agoston S. 4-Aminopyridine kinetics. Clin. Pharmacol. Ther. 1982, 31:587-593.
42. Smith W., Swan S., Marbury T., Henney H. Single-dose pharmacokinetics of sustained-release fampridine (Fampridine-SR) in healthy volunteers and adults with renal impairment. J. Clin. Pharmacol. 2010, 50:151-159.
43. Bostock H., Sherratt R.M., Sears T.A. Overcoming conduction failure in demyelinated nerve fibres by prolonging action potentials. Nature 1978, 274:385-387.
44. Targ E.F., Kocsis J.D. Action potential characteristics of demyelinated rat sciatic nerve following application of 4-aminopyridine. Brain Res. 1986, 363:1-9.
45. Koschak A., Bugianesi R.M., Mitterdorfer J., Kaczorowski G.J., Garcia M.L., Knaus H.G. Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom. J. Biol. Chem. 1998, 273:2639-2644.
46. Schmidt K., Eulitz D., Veh R.W., Kettenmann H., Kirchhoff F. Heterogeneous expression of voltage-gated potassium channels of the shaker family (Kv1) in oligodendrocyte progenitors. Brain Res. 1999, 843:145-160.
47. Thomsen R.H., Wilson D.F. Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J. Pharmacol. Exp. Ther. 1983, 227:260-265.
48. Bever C.T., Young D., Anderson P.A., Krumholz A., Conway K., Leslie J., Eddington N., Plaisance K.I., Panitch H.S., Dhib-Jalbut S., et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994, 44:1054-1059.
49. Bruck W., Kuhlmann T., Stadelmann C. Remyelination in multiple sclerosis. J. Neurol. Sci. 2003, 206:181-185.
50. Patrikios P., Stadelmann C., Kutzelnigg A., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Bruck W., Lucchinetti C., Lassmann H. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
51. Levine J.M., Reynolds R., Fawcett J.W. The oligodendrocyte precursor cell in health and disease. Trends Neurosci. 2001, 24:39-47.
52. Chang A., Nishiyama A., Peterson J., Prineas J., Trapp B.D. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J. Neurosci. 2000, 20:6404-6412.
53. John G.R., Shankar S.L., Shafit-Zagardo B., Massimi A., Lee S.C., Raine C.S., Brosnan C.F. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 2002, 8:1115-1121.
54. Chittajallu R., Chen Y., Wang H., Yuan X., Ghiani C.A., Heckman T., Mcbain C.J., Gallo V. Regulation of Kv1 subunit expression in oligodendrocyte progenitor cells and their role in G1/S phase progression of the cell cycle. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2350-2355.
55. Ghiani C.A., Yuan X., Eisen A.M., Knutson P.L., Depinho R.A., Mcbain C.J., Gallo V. Voltage-activated K+channels and membrane depolarization regulate accumulation of the cyclin-dependent kinase inhibitors p27(Kip1) and p21(CIP1) in glial progenitor cells. J. Neurosci. 1999, 19:5380-5392.
56. Vautier F., Belachew S., Chittajallu R., Gallo V. Shaker-type potassium channel subunits differentially control oligodendrocyte progenitor proliferation. GLIA 2004, 48:337-345.
57. Herrero-Herranz E., Pardo L.A., Bunt G., Gold R., Stuhmer W., Linker R.A. Re-expression of a developmentally restricted potassium channel in autoimmune demyelination: Kv1.4 is implicated in oligodendroglial proliferation. Am. J. Pathol. 2007, 171:589-598.
58. Davis F.A., Stefoski D., Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 1990, 27:186-192.
59. Hansebout R.R., Blight A.R., Fawcett S., Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J. Neurotrauma. 1993, 10:1-18.
60. Sanders D.B., Massey J.M., Sanders L.L., Edwards L.J. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000, 54:603-607.
61. Wirtz P.W., Verschuuren J.J., Van Dijk J.G., De Kam M.L., Schoemaker R.C., Van Hasselt J.G., Titulaer M.J., Tjaden U.R., Den Hartigh J., Van Gerven J.M. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin. Pharmacol. Ther. 2009, 86:44-48.
62. Tibbs G.R., Barrie A.P., Van Mieghem F.J., Mcmahon H.T., Nicholls D.G. Repetitive action potentials in isolated nerve terminals in the presence of 4-aminopyridine: effects on cytosolic free Ca2+ and glutamate release. J. Neurochem. 1989, 53:1693-1699.
63. Wu Z.Z., Li D.P., Chen S.R., Pan H.L. Aminopyridines potentiate synaptic and neuromuscular transmission by targeting the voltage-activated calcium channel beta subunit. J. Biol. Chem. 2009, 284:36453-36461.
64. Smith K.J., Felts P.A., John G.R. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000, 123(Pt 1):171-184.
65. Khanna R., Roy L., Zhu X., Schlichter L.C. K+ channels and the microglial respiratory burst. Am. J. Physiol. Cell Physiol. 2001, 280:C796-C806.
66. Kotecha S.A., Schlichter L.C. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J. Neurosci. 1999, 19:10680-10693.
67. Decoursey T.E., Chandy K.G., Gupta S., Cahalan M.D. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis?. Nature 1984, 307:465-468.
68. Grissmer S., Hanson D.C., Natoli E.J., Cahalan M.D., Chandy K.G. CD4-CD8- T cells from mice with collagen arthritis display aberrant expression of type l K+ channels. J. Immunol. 1990, 145:2105-2109.
69. Fischer H.G., Eder C. Voltage-gated K+ currents of mouse dendritic cells. FEBS Lett. 1995, 373:127-130.
70. Chandy K.G., Decoursey T.E., Cahalan M.D., Mclaughlin C., Gupta S. Voltage-gated potassium channels are required for human T lymphocyte activation. J. Exp. Med. 1984, 160:369-385.
71. Nisbet-Brown E.R., Lee J.W., Cheung R.K., Gelfand E.W. Antigen-specific and -nonspecific mitogenic signals in the activation of human T cell clones. J. Immunol. 1987, 138:3713-3719.
72. Decoursey T.E., Chandy K.G., Gupta S., Cahalan M.D. Mitogen induction of ion channels in murine T lymphocytes. J. Gen. Physiol. 1987, 89:405-420.
73. Chandy K.G., Cahalan M.D., Grissmer S. Autoimmune diseases linked to abnormal K+ channel expression in double-negative CD4-CD8- T cells. Eur. J. Immunol. 1990, 20:747-751.
74. Mix E., Olsson T., Solders G., Link H. Effect of ion channel blockers on immune response and course of experimental allergic neuritis. Brain 1989, 112(Pt 6):1405-1418.
75. Lewis R.S., Cahalan M.D. Potassium and calcium channels in lymphocytes. Annu. Rev. Immunol. 1995, 13:623-653.
76. Ghanshani S., Wulff H., Miller M.J., Rohm H., Neben A., Gutman G.A., Cahalan M.D., Chandy K.G. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. J. Biol. Chem. 2000, 275:37137-37149.
77. Cahalan M.D., Wulff H., Chandy K.G. Molecular properties and physiological roles of ion channels in the immune system. J. Clin. Immunol. 2001, 21:235-252.
78. Rus H., Pardo C.A., Hu L., Darrah E., Cudrici C., Niculescu T., Niculescu F., Mullen K.M., Allie R., Guo L., Wulff H., Beeton C., Judge S.I., Kerr D.A., Knaus H.G., Chandy K.G., Calabresi P.A. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11094-11099.
79. Wulff H., Calabresi P.A., Allie R., Yun S., Pennington M., Beeton C., Chandy K.G. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J. Clin. Invest. 2003, 111:1703-1713.
80. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., Wang P.H., Leehealey C.J., S.A.B, Sankaranarayanan A., Homerick D., Roeck W.W., Tehranzadeh J., Stanhope K.L., Zimin P., Havel P.J., Griffey S., Knaus H.G., Nepom G.T., Gutman G.A., Calabresi P.A., Chandy K.G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17414-17419.
81. Wulff H., Pennington M. Targeting effector memory T-cells with Kv1.3 blockers. Curr. Opin. Drug Discov. Dev. 2007, 10:438-445.
82. Judge S.I., Yeh J.Z., Mannie M.D., Pope Seifert L., Paterson P.Y. Potassium channel blockers inhibit adoptive transfer of experimental allergic encephalomyelitis by myelin-basic-protein-stimulated rat T lymphocytes. J. Biomed. Sci. 1997, 4:169-178.
83. Beeton C., Barbaria J., Giraud P., Devaux J., Benoliel A.M., Gola M., Sabatier J.M., Bernard D., Crest M., Beraud E. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 2001, 166:936-944.
84. Beeton C., Wulff H., Barbaria J., Clot-Faybesse O., Pennington M., Bernard D., Cahalan M.D., Chandy K.G., Beraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13942-13947.
85. Panyi G., Bagdany M., Bodnar A., Vamosi G., Szentesi G., Jenei A., Matyus L., Varga S., Waldmann T.A., Gaspar R., Damjanovich S. Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2592-2597.
86. Gong J., Xu J., Bezanilla M., Van Huizen R., Derin R., Li M. Differential stimulation of PKC phosphorylation of potassium channels by ZIP1 and ZIP2. Science 1999, 285:1565-1569.
87. Szabo I., Gulbins E., Apfel H., Zhang X., Barth P., Busch A.E., Schlottmann K., Pongs O., Lang F. Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. J. Biol. Chem. 1996, 271:20465-20469.
88. Hanada T., Lin L., Chandy K.G., Oh S.S., Chishti A.H. Human homologue of the Drosophila discs large tumor suppressor binds to p56lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes. J. Biol. Chem. 1997, 272:26899-26904.
89. Chandy K.G., Wulff H., Beeton C., Pennington M., Gutman G.A., Cahalan M.D. K+ channels as targets for specific immunomodulation. Trends Pharmacol. Sci. 2004, 25:280-289.
90. Panyi G., Vamosi G., Bacso Z., Bagdany M., Bodnar A., Varga Z., Gaspar R., Matyus L., Damjanovich S. Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:1285-1290.
91. Levite M., Cahalon L., Peretz A., Hershkoviz R., Sobko A., Ariel A., Desai R., Attali B., Lider O. Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J. Exp. Med. 2000, 191:1167-1176.
92. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
93. Goverman J., Perchellet A., Huseby E.S. The role of CD8(+) T cells in multiple sclerosis and its animal models. Curr. Drug Targets Inflamm. Allergy 2005, 4:239-245.
94. Friese M.A., Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 2005, 128:1747-1763.
95. Malmestrom C., Lycke J., Haghighi S., Andersen O., Carlsson L., Wadenvik H., Olsson B. Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSF. J. Neuroimmunol. 2008, 196:159-165.
96. Wang T., Lee M.H., Johnson T., Allie R., Hu L., Calabresi P.A., Nath A. Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J. Neurosci. 2010, 30:5020-5027.
97. Corcione A., Casazza S., Ferretti E., Giunti D., Zappia E., Pistorio A., Gambini C., Mancardi G.L., Uccelli A., Pistoia V. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11064-11069.
98. Wulff H., Knaus H.G., Pennington M., Chandy K.G. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J. Immunol. 2004, 173:776-786.
99. Zozulya A.L., Clarkson B.D., Ortler S., Fabry Z., Wiendl H. The role of dendritic cells in CNS autoimmunity. J. Mol. Med. 2010, 88:535-544.
100. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001, 106:263-266.
101. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
102. Mullen K.M., Rozycka M., Rus H., Hu L., Cudrici C., Zafranskaia E., Pennington M.W., Johns D.C., Judge S.I., Calabresi P.A. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Ann. Neurol. 2006, 60:118-127.
103. Langenkamp A., Messi M., Lanzavecchia A., Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 2000, 1:311-316.
104. Gonzalez-Scarano F., Baltuch G. Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 1999, 22:219-240.
105. Benveniste E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. 1997, 75:165-173.
106. Fordyce C.B., Jagasia R., Zhu X., Schlichter L.C. Microglia Kv1.3 channels contribute to their ability to kill neurons. J. Neurosci. 2005, 25:7139-7149.
107. Koeberle P.D., Schlichter L.C. Targeting K(V) channels rescues retinal ganglion cells in vivo directly and by reducing inflammation. Channels (Austin) 2010, 4.
108. Aloisi F. Immune function of microglia. GLIA 2001, 36:165-179.
109. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. GLIA 2002, 40:133-139.
110. Decoursey T.E., Kim S.Y., Silver M.R., Quandt F.N. Ion channel expression in PMA-differentiated human THP-1 macrophages. J. Membr. Biol. 1996, 152:141-157.
111. Vicente R., Escalada A., Coma M., Fuster G., Sanchez-Tillo E., Lopez-Iglesias C., Soler C., Solsona C., Celada A., Felipe A. Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J. Biol. Chem. 2003, 278:46307-46320.
112. Schlichter L., Sidell N., Hagiwara S. Potassium channels mediate killing by human natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:451-455.
113. Sidell N., Schlichter L.C., Wright S.C., Hagiwara S., Golub S.H. Potassium channels in human NK cells are involved in discrete stages of the killing process. J. Immunol. 1986, 137:1650-1658.